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SUMMARY The prophylactic antianginal efficacy of nitroglycerin (NTG) oral spray was assessed in 20 patients with angiographically documented coronary disease and stable angina pectoris. The evaluation was by a randomized crossover trial involving treadmill exercise testing. On study day 1, a control treadmill exercise test was performed, followed 30 minutes later by a second exercise test 2 minutes after administration of either placebo (group A, 10 patients) or NTG spray 0.8 mg (group B, 10 patients). One week later, on study day 2, the patients again underwent control treadmill exercise testing followed by a second exercise test after either NTG spray (group A) or placebo (group B). NTG spray delayed the onset of anginal pain during exercise by a mean of 100 64 seconds (p < 0.001) in 13 patients and prevented pain entirely in seven. Placebo did not significantly delay the appearance of angina and prevented chest pain in only one patient. NTG spray increased treadmill exercise duration by 31% before the onset of angina (p < 0.001); placebo did not significantly alter the duration of exercise. NTG spray abolished in six patients and delayed in 14 patients the onset of exercise-induced ST-segment depression of 1 mm (p < 0.001). Patients achieved a higher heart rate at peak exercise with NTG spray, and yet the maximal exercise-induced ST-segment depression of 2.1 + 1.0 mm during the control study declined to 1.3 + 0.9 mm on NTG spray (p < 0.001). Placebo had no effect on exercise ST-segment depression. These data indicate that the oral NTG spray is an effective prophylactic for exercise-induced angina.
THE MAINSTAY of treatment for angina pectoris for the last hundred years has been nitroglycerin (NTG). I NTG reliably relieves angina and augments exertional tolerance when used prophylactically.2" When administered sublingually in tablet, NTG reaches peak blood levels 2 minutes after its dissolution.7 However, the time required for the tablet to dissolve varies from person to person and further delays the onset of action for pain relief. NTG oral spray theoretically should eliminate the time required for tablet dissolution. When sprayed onto the tongue, it is directly absorbed and thus might afford more rapid and reliable action.
We assessed the therapeutic efficacy of NTG spray in patients with exercise-induced angina and obtained subjective and objective measurements during tread-mill exercise testing. Our initial experience with NTG spray has been presented in preliminary form.8
Methods

Patients
Twenty patients (17 males and three females), mean age 61 years (range 50-74 years), with stable, exercise-induced angina pectoris participated in this trial. Their history of angina ranged from 6 months to 12 years (average 44 months). All patients had angiographically demonstrable coronary artery disease, and had at least 70% narrowing of luminal diameter in at least one major coronary artery. Ten patients had had a myocardial infarction at least 6 months before the study. Five patients had undergone coronary artery bypass graft surgery but continued to have stable angina. None of the patients were hypertensive or had clinical or radiologic evidence of heart failure. All patients had undergone treadmill exercise testing within 6 months before the study; treadmill exercise-induced angina and ischemic ST depression of 1.0 mm or more lasting at least 0.08 second occurred in each patient. All In the sitting position 1 minute after NTG spray, there was no significant change in heart rate compared with control. However, 2 minutes after administration of NTG spray in the standing position, mean heart rate increased significantly (p < 0.01). Placebo spray did not increase heart rate either in the sitting or standing position. Systolic blood pressure declined significantly after NTG spray in the sitting and standing positions (p < 0.001). Placebo spray had no significant effect on systolic blood pressure in the standing position.
Effect on Exercise-induced Angina and Exercise Tolerance NTG spray relieved symptoms in all 20 patients. The onset of angina was delayed by a mean of 100 ± 64 seconds (p < 0.001) in 13 patients and pain was totally prevented in seven patients. Placebo delayed the onset of angina in 11 patients, but the magnitude of the delay was not significant (17 + 39 seconds); placebo prevented angina in only one patient.
Exercise tolerance as assessed by maximal exercise duration improved significantly after NTG. NTG spray extended exercise duration 31%, from 321 + 97 to 420 + 111 seconds (p < 0.001). In contrast, there was no significant alteration after placebo compared with control (300 ± 97 vs 312 + 97 seconds).
Estimated maximal total body oxygen consumption (VO2 max) at peak exercise increased from 24.1 + 3.8 to 27.6 ± 4.9 ml/kg/min (p < 0.001) after NTG spray, but did not significantly change after placebo (22.9 + 3.7 to 23.4 + 3.8 ml/kg/min).
Hemodynamic Data at Maximal Exercise
Maximal heart rate increased in all patients after *Chest pain scale: 0 = no pain; 1 + = mild pain; 2 + = moderate pain; 3 + = moderately severe pain (or equivalent to that which usually necessitated discontinuation of activity); 4 + = very severe pain equivalent to the most severe pain the patient had experienced. Measurements in the sitting position were taken 1 minute after administration of nitroglycerin or placebo. Measurements in the standing position were taken 2 minutes after administration of nitroglycerin or placebo.
NTG spray. The mean increase was 12% (122 ± 19 to 137 + 19 beats/min, p < 0.001), whereas there was no difference after placebo (118 ± 19 vs 120 ± 21 beats/min).
Maximal exercise double product increased after NTG spray (23.2 ± 3.7 x 103vs 20.7 ± 3.6 x 103,p < 0.01). There was no significant change in double product after placebo spray.
ST-segment Depression at Maximal Exercise
During control exercise testing, all patients had at least 1 mm of ST-segment depression. NTG spray delayed the onset of 1 mm of ST depression in 14 patients. On the average, ST-segment depression appeared between the third and fourth minutes of control exercise (mean 3.6 ± 1.3 minutes, median 3.7 minutes) and between the fifth and sixth minutes (mean 5.6 ± 1.8 minutes, median 6.1 minutes) of exercise after NTG spray (p < 0.001). In the remaining six patients, ST-segment depression was totally abolished after NTG spray. Placebo did not significantly delay or prevent ST-segment depression.
Maximal exercise-induced ST-segment depression was reduced significantly after NTG spray (2.1 ± 1.0 to 1.3 ± 0.9 mm, p < 0.001) despite a higher work load in the NTG-treated group. Placebo had no effect on ST-segment depression at peak exercise (2.0 ± 0.9 [placebo] and 1.9 ± 0.9 mm [control]).
Adverse Side Effects
Only three patients complained of headaches after NTG spray. All 20 patients completed the study without experiencing major adverse side effects.
Discussion
This study demonstrates the prophylactic antianginal efficacy of NTG oral spray in patients with documented coronary artery disease and exerciseinduced angina pectoris. This new mode of NTG application significantly increased treadmill exercise duration and work load before the onset of angina compared with placebo spray. The magnitude of improvement in exercise duration (31 %) in our patients is consistent with the beneficial effect of sublingual NTG demonstrated by others."2 The reduction of blood pressure in both the sitting and standing positions and elevation of heart rate in the standing position parallel the characteristic hemodynamic changes observed after sublingual NTG, indicating absorption and pharmacologic activity of the drug in the spray form. The hemodynamic effects were rapid in onset (less than 2 minutes).
Previous studies have indicated that the antianginal action of NTG derives principally from reduction of myocardial oxygen demand through diminution of myocardial wall tension.'1 12 This effect results from the peripheral arteriolar and venous dilating actions of the drug, which reduce systolic blood pressure and ventricular volume, the major determinants of myocardial wall tension.4 13,14 Alleviation of myocardial ischemia and angina results from improvement in the relationship between myocardial oxygen supply and demand after reduction in the latter. A favorable effect on the distribution of myocardial blood flow after NTG has also been suggested, but reduction of cardiac oxygen demand appears to be the principal antianginal mechanism of the drug.4 15 The oral spray is a new and effective modality of achieving the effects of NTG. In theory, the NTG spray affords greater stability than sublingual tablets because the spray is a lipid solution in a metal container and is administered by metered dose. In contrast, repeated opening of a bottle of sublingual NTG tablets can accelerate chemical breakdown of glyceryl trinitrate to less active compounds by exposure to atmospheric heat, light and moisture. Further, administration of NTG oral spray is safe. No adverse effect was experienced by patients receiving NTG oral spray in this investigation.
The encouraging results of our single-blind, randomized, crossover study warrant double-blind analysis of oral NTG spray in a larger number of patients. and women younger than 50 years of age with myocardial infarction (MI). Heterozygous parents of children with one type of familial hypercholesterolemia have early onset of CHD while children who are homozygous often suffer a fatal MI before age 20 years.' In a community-wide study, the rate of a first major coronary event in white adult males during a 10-year follow-up increased uniformly with an increase in initial cholesterol levels.4 Both the low-density lipoprotein (LDL) and high-density lipoprotein (HDL) fractions of serum cholesterol are stronger predictors of CHD in men older than age 50 years than is total cholesterol.5 Although an elevated LDL level appears to be atherogenic, an elevated HDL level may be antiatherogenic.6
Studies in children have provided frequency distributions of lipids and lipoproteins by age and sex7 and evidence that a person's cholesterol levels measureci 2
